RAC 2.20% $1.78 race oncology ltd

General Comments / Chat, page-10299

  1. 456 Posts.
    lightbulb Created with Sketch. 689
    Yes. I would need DT to clarify, but it sounds like P1 data (despite P2 not being underway, let alone delivered) will be enough to garner FDA approval, through clever endpoint/outcome goals.

    So, again explains why we are opening the FDA IND this year. 24 months(ish).
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.